Abstract
Asenapine is a sublingually absorbed newer second-generation antipsychotic that is approved for the treatment of schizophrenia and bipolar disorder in patients, with a lower extrapyramidal adverse effect potential. We report an adolescent boy having schizophrenia who developed an acute dystonic reaction after 4 days when the dose of asenapine was increased from 10 to 15 mg per day.
Original language | English |
---|---|
Pages (from-to) | 955-956 |
Number of pages | 2 |
Journal | Journal of Child and Adolescent Psychopharmacology |
Volume | 26 |
Issue number | 10 |
DOIs | |
Publication status | Published - 01-12-2016 |
All Science Journal Classification (ASJC) codes
- Pediatrics, Perinatology, and Child Health
- Psychiatry and Mental health
- Pharmacology (medical)